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Abstract
Background: Kaposi’s sarcoma (KS), an endothelial neoplasm, is associated with human herpes virus (HHV) -8
infection. KS has four clinical sub-types: Mediterranean/classic, African/endemic, human immunodeficiency virus
(HIV) -associated/epidemic, and transplantation-related/iatrogenic. Immunosuppression is an important cofactor in
KS process. Classic KS (CKS) is exceedingly rare in children and when occurs, it is much more disseminated than
adults. The epidemic, HIV-associated and the iatrogenic forms of childhood KS are a result of a profound and
acquired T-cell deficiency. To our knowledge, this is the first paediatric KS case report from Iraq. Our patient was
showing an unusual aggressive course of the disease while receiving Valproic acid (VPA) of the potential
immune-suppressive effect.
Case presentation: A six-year-old Iraqi boy, who had cerebral palsy (CP) and epilepsy since the age of 9-months,
had received VPA to control his seizures. He developed skin discoloration followed by nodules that disseminated
proximally from the lower extremities to the groin, face, ears and oral cavity, and then he died from severe
respiratory distress after 110 days from the disease evolution. KS diagnosis was proved by a skin biopsy. As the
patient was of Arab-Asian ethnicity and was HIV-seronegative status, accordingly, his condition best fitted the
classic form of KS. However, recent studies showed the link of VPA with the reactivation of HHV-8. Moreover,
accumulated experimental and clinical data elucidated that VPA induces T-cell suppression. Given that there was a
lack of facilities to perform the laboratory immunological diagnostic tests in Iraq, the VPA-induced effect on
immunity in our case (iatrogenic KS) could not be evaluated.
Conclusions: Our report demonstrates a rare, rapidly progressing paediatric KS case and highlights the possible
role of the 5-years’ administration of VPA and its challenging effect on cellular immunity based on recent studies.
Thus, VPA could have promoted the development of the KS in our patient. This report also recalls the need of
paediatricians to consider KS especially when the skin lesion appears at the child’s foot even in countries outside
the geographical map of the disease.
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Background
Kaposi’s sarcoma (KS), an endothelial neoplasm, was first
reported by Moritz Kaposi in 1872 [1]. Chang et al., in
1994, isolated KS-associated herpesvirus, also known as
human herpesvirus (HHV) -8, from KS lesion [2]. KS has
four clinical sub-types: Mediterranean/classic, African/en-
demic, human immunodeficiency virus (HIV) -associated/
epidemic, and transplantation-related/iatrogenic [3, 4].
Classic KS (CKS) is generally an indolent disease involving
the dermis of the lower extremities, and affects predomin-
antly elderly men of Mediterranean, Eastern European,
and Jewish heritage, but it is exceedingly rare in children
[1, 5]. Worldwide occasional cases of paediatric CKS have
been reported, revealing a more disseminated form than
adult CKS [6]. Moreover, the course may be more rapid
when the viscera are involved, due not to greater
aggressiveness, but to complications including haemor-
rhage [7, 8]. In advanced cases, the lesions may spread to
ears, fingers, and mucous membranes. Lymph nodes and/
or visceral involvement may subsequently occur [9]. Pul-
monary involvement in KS occurs commonly in immuno-
suppressed patients, who usually have had preceding
mucocutaneous involvement [10–12]. African/endemic
KS follows a more severe course and is common in Sub-
Saharan Africa, it affects younger adults with a rapidly
progressive lymphadenopathic course [4]. Epidemic and
Iatrogenic KS, which generally show the most severe
courses, remain relatively rare in children [5, 10, 13]. The
iatrogenic type of KS, also called immunosuppression-
associated KS, can be triggered by medical treatment
using immunosuppressant medications, for various rea-
sons including post-organ transplantation. The epidemic
and iatrogenic forms of childhood KS result from a pro-
found and acquired T cell deficiency [14].
Of note, KS is >100 times more common in immuno-
suppressed individuals. Loss of T-cell-mediated immune
control allows HHV-8-infected cells to proliferate un-
checked and thus the tumours to develop [15].
The prevalence of HHV-8 varies geographically; with a
seropositivity level exceeds 40 % in parts of Africa and
South America, ranges from 30 %–40 % in the Mediter-
ranean Basin, and drops to 20 % in non-endemic areas
such as North America, Northern Europe, and most of
Asia. However, the vast majority of HHV-8 infected indi-
viduals (more than 40 % of individuals in some popula-
tions, based on seroprevalence) do not develop KS. The
epidemiology of HHV-8 infection and development of
iatrogenic KS in the paediatric population has not been
fully elucidated yet [14]. Unfortunately, due to lack of
diagnostic facilities, information is not yet available in
regard to the epidemiology of HHV-8 in Iraq.
The following is a paediatric KS case from Iraq who
was showing an unusual aggressive course of the disease
while receiving Valproic acid (VPA) of the potential
immune-suppressive effect. To our knowledge this is the
first paediatric KS case report from Iraq.
Case presentation
A 6-year-old Iraqi boy of Arab-Asian ethnicity who had de-
veloped cerebral palsy (CP) with mental retardation and
epilepsy after encephalitis at the age of 9 months. Since that
time, he had been treated with oral VPA (30 mg/kg/day,
twice a day) to control the seizures. His family history was
unremarkable apart from that his next older brother had
acute lymphoblastic leukaemia and died due to severe in-
fection a year and a half before the birth of this case of KS.
Our patient was the youngest among 4 siblings of healthy
second-cousin parents. The other 2 older siblings are
healthy. Our patient suffered from recurrent respiratory
tract infections and was hospitalized twice. The latest epi-
sode was on December 1st, 2013 when he was 6 years-old.
Although he had middle lobe atelectasis, he responded well
to a 1-week treatment with non-specific antibiotic and his
chest roentgenogram showed improvement.
One week after being discharged from the hospital,
painless skin lesions appeared in the form of a bluish-
purple plaque (blue-violet to black hue) on the middle
and little toes of his left foot and extended to the upper
lateral sole area (Fig. 1a). Physical examination revealed a
spastic quadriplegic type of CP, mentally subnormal with
open mouth, mouth breathing, and misalignment of the
teeth with malocclusion. He was in full-body hypertonia
with legs being affected more than arms and hyperreflexia
with clonus. Systemic examination of the chest revealed
harsh vesicular breath sound and normal heart sounds.
His abdomen was soft, with no organomegaly, mass or
free fluid. The investigations performed included complete
blood count, blood film, erythrocyte sedimentation rate,
coagulation profile, blood chemistry, liver and renal work-
up, urinalysis, chest x-ray and ultrasound examination of
the abdomen were all normal. Serological screening for
hepatitis B and C as well as HIV was negative.
In January 2014, palpable bluish-purple nodules ap-
peared on the left leg and then on the right leg. The skin
discoloration extended to the plantar surface, and edema
of the left foot became obvious (Fig. 1b), but peripheral
arterial pulse and the perfusion in the lower extremities
were intact. A skin biopsy was taken on February 15th,
2014 from the lesion on the left foot, thereafter the pa-
tient experienced pain. During February and March
2014, new skin nodules appeared in an ascending pat-
tern: 2 around the groin, 2 on the left arm, 1 in the right
sub-axillary area, and on the face (medial angle of left
eye and both ear cartilages) (Fig. 1c, d). Small cervical
lymphadenopathy also became palpable. Meanwhile, a
purple, slightly elevated lesion erupted on the hard pal-
ate. He was kept on his VPA dose with no additional
therapy apart from analgesic agents, as the family
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Fig. 1 Clinical progress of the patient. Skin discoloration of KS on the toes of the left foot, then a nodule appeared on left leg arrowed (a). The
lesion extended to plantar surface with left leg edema encircled (b). New nodules appeared at the groin and right axilla (indicated by arrows) (c).
KS nodules appeared on face, ears, and the angle of the left eye (indicated by arrows) (d)
Fig. 2 Skin biopsy findings. Spindle cells were closely associated with narrow vascular spaces, numerous erythrocytes and few inflammatory cells
(H&E) (a). Some of the spindle cells showed nuclear expression of HHV-8 (b). Most of the spindle cells showed apparent expression of CD34 and
CD31 (c, d)
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Table 1 Pediatric classic Kaposi’s sarcoma in literature review
Variable KS with skin lesion KS with no skin lesion Total
number = 32 number = 4
Origin Mediterranean Basin Other countries Mediterranean Basin Other countries
22 10 2 2 36
Age
0- < 10 11 7 1 2 21
10- < =15 8 3 1 0 12
NA 3 0 0 3
Sex
Male 15 8 2 2 27
Female 6 1 0 0 7
NA 1 1 0 0 2
Clinical findings
Lymph node (s)
Yes 10 1 0 2 13
No 2 5 0 0 7
NA 10 4 2 0 16
Visceral involvement
Yes 8 3 1 2 14
No 6 4 1 0 11
NA 8 3 0 0 11
Diagnosis
Skin biopsy 18 8 0 0 26
Lymph node biopsy 1 a 0 1 2 3
NA 4 2 1 0 7
HHV-8 status
Positive 12 2 0 0 14
Negative 1 b 0 0 0 1
Non-conclusive 1 0 0 0 1
Test not yet available (old reports) 8 8 2 2 20
Immunity status
Identified Immunodeficiency 5 0 0 0 5
1- IFN-gamma-R1 deficiency 2 0 0 0
2- Wiskott-Aldrich syndrome 2 0 0 0
3- Inherited human OX40 deficiency 1 0 0 0
Unidentified Immunodeficiency 2 2 0 0 4
NA 15 8 2 2 27
Treatment
Given treatment 21
No treatment 1 1 0 0 2
NA 6 5 2 0 13
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refused hospital admission. On April 3rd, 2014 the pa-
tient had developed sudden respiratory distress, and died
before arrival to the hospital just 3 days before getting
his final biopsy test results.
The skin biopsy material was re-evaluated in Japan be-
cause of the lack of facilities for HHV-8 detection in
Iraq. The results are presented in Fig. 2, the spindle cells
reacted with monoclonal antibodies against CD34 and
CD31 antigens. Additionally, these cells were positive for
HHV-8, hence the diagnosis of KS was confirmed. The
“CARE” checklist is available as Additional file 1. This
child’s clinical course is summarized in the accompany-
ing supplemental time-line file (Additional file 2).
Discussion
Given the accessible published literatures since 1960 ex-
cluding African, iatrogenic and HIV-associated KS, there
were 36 paediatric KS cases of 15 years of age or younger
including our case were identified. Of them, 32 had skin
lesions and 4 had no skin lesion [5–9, 11–13, 16–31].
Twenty-four (67 %) of 36 KS patients belonged to the
Mediterranean Basin, including Turkey (8 cases) and Italy
(7 cases) as shown in Table 1. Two-thirds of patients were
under 10-years old, and there was a male gender predom-
inance with 75 % being boys. Skin lesion was the first clin-
ical presentation in 75 % of the cases, lymph nodes were
palpable in 65 %, and visceral involvement was reported in
more than half of the cases.
KS was diagnosed on the basis of skin biopsies demon-
strating the presence of spindle cells in 90 % of cases.
HIV was negative in all 26 examined cases, and HHV-8
was positive in 87.5 % of the examined cases. Within the
collected series, 16 (64 %) of 25 cases with known out-
come were reported as survivors, including two cases
rescued by Hematopoietic stem cell transplantation, and
five of the 16 survivors had coexisted identified im-
munodeficiency. The remaining 9 cases were reported
dead, eight of them had visceral involvement and five of
them died within < 6 months of the onset of the disease.
In our patient, KS was suspected by the evolution
from a macular stage, with characteristic colour, multi-
focal distribution and the presence of lesions on the toes.
The diagnosis was made by the characteristic skin biopsy
findings along with immunohistochemical detection of
HHV-8.
Regarding the risk factors in our patient, it is well
known that the development of KS is a multifactorial
process in which HHV-8 infection is a prerequisite and an
immunosuppression is an important cofactor [12, 32, 33].
Recently, Gorres et al., reported the link of VPA with the
reactivation of HHV-8 from latency. Thus, the virus could
persist and spread among hosts’ cells, and therefore could
play a role in carcinogenesis [34]. Accumulated experi-
mental and clinical data also showed that VPA induces T-
cell suppression via a direct effect and effectively reduces
the expression of pro-inflammatory cytokines such as
IFN- [35]. Therefore, a possible risk factor for develop-
ing KS might be the use of VPA in our case. However,
given that there was a lack of facilities to perform labora-
tory immunological diagnostic tests in Iraq, the VPA-
induced (iatrogenic) effect on immunity in our particular
case could not be proved. Moreover, if we take into con-
sideration his previous history of encephalitis, which
might be of herpes simplex etiology and his repeated re-
spiratory tract infections, then single-gene immunodefi-
ciencies could not be excluded as a predisposing factor for
KS according to literatures as well [14].
CKS has been reported in two isolated studies among
Iraqi adults: a 21-patient report over a 10 year period
(1974–1984) and a more aggressive 20-case report over
a shorter period (1999–2001) with a predilection for
younger age [36]. Taken together, the increased number
of cases along with the aggressive behaviour of CKS in
Iraq suggested a potential environmental factor. De-
pleted uranium (DU) has been used in Iraq since 1991
(the first Gulf War) contaminating the environment
through its radioactive and toxic effects. A possible rela-
tionship between KS and DU has been suggested by
Shelleh [37]. Since children are more susceptible to radi-
ation than adults, a possible role of DU in the develop-
ment of KS cannot be excluded in our case.
Finally, despite the scarcity of the KS and the shortage
of the diagnostic tools in Iraq, diagnosis of KS was pos-
sible with multiple consultations and cooperation from
inside and outside Iraq and then it was proved in Japan.
In reference to KS subtype, our patient was of Arab-
Asian ethnicity, and was HIV-seronegative, accordingly,
his condition could be categorized as a classic form of
KS; however, the iatrogenic VPA-induced-KS could not
be excluded.
Table 1 Pediatric classic Kaposi’s sarcoma in literature review (Continued)
Outcome
Survived 10 5 0 1 16
Dead 6 1 1 1 9
NA 6 4 1 0 11
HHV-8 Human herpes virus-8, IFN Interferon, KS Kaposi’s sarcoma, NA not available
aOne case with skin and lymph node biopsy
b(reference 18, 1999)
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Conclusion
Our report demonstrates one of the rare, rapidly pro-
gressing paediatric KS and highlights the possible role of
the 5-years’ administration of VPA and its challenging
effect on cellular immunity based on recent studies.
Thus, VPA could have promoted the development of the
KS in our patient. This report also recalls the need of
paediatricians to consider KS especially when the skin
lesion appears at the child’s foot even in countries out-
side the geographical map of the disease.
Additional files
Additional file 1: CARE checklist of information to include when writing
a case report. (DOC 1547 kb)
Additional file 2: Time-line table. Summarization of the child’s clinical
course. (DOCX 48 kb)
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